HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Church & Dwight Shapes Potential OTC Play On Gummy Format

This article was originally published in The Tan Sheet

Executive Summary

The firm says sales of L’il Critters children’s and Vitafusion adults’ gummy vitamin lines increased more than 7% in its fiscal 2015 third quarter from the year-ago period as production and distribution began recovering from disruptions that restrained sales in the previous quarter.

You may also be interested in...



US House Appropriators Request CBD Enforcement As They Ante Up $5M For FDA's Rule Development

Appropriation Committee members target $5m for FDA's CBD policy work and suggest the agency enforce against noncompliant firms in their report accompanying legislation proposing the agency’s fiscal 2021 budget. 

New Report, Same Theme On US FDA's Policy On Cannabidiols: ‘Extensive Data Gaps’ On Safety

FDA’s second report to Congress on oversight of CBD market includes results from studies of whether products are mislabeled or adulterated, but also indicates throughout that more data are needed on safety of hemp-derived CBD ingredients used in myriad consumer health, cosmetic and food products already available.

OTC Loperamide Cardiovascular Label Warnings In US Spread To Perrigo Products

FDA approval for Perrigo's ANDA for two loperamide products listed as tablets follows CBE label changes Johnson & Johnson and BionPharma made for their branded OTCs containing the ingredient in 2019.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel